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The Kidney in Sickle Cell Disease:
Pathophysiology and Clinical Review
Ibrahiem Saeed Abdulrahman
Sickle cell disease is a major health problem in many countries. Sickled erythrocytes in the renal medullary ves-
sels are the hallmark of the disease, and are associated with a variety of renal complications. Renal ischemia,
microinfarcts and papillary necrosis occur, and renal tubular abnormalities follow. Glomerular disease with
proteinuria may be observed. Renal failure, both acute and chronic, is the expected outcome of the disease.
Hematuria, electrolyte and acid base disturbances are common throughout the course of the disease. End-stage
renal disease as a complication of aggressive sickle cell disease should be treated with dialysis or kidney
transplantation; both are effective. There is a tendency towards better survival in sickle cell nephropathy patients
undergoing transplantation than in those treated with hemodialysis alone. Whether bone marrow transplantation
in the early stage of the disease can halt the progression of sickle cell nephropathy is unknown and awaits
clinical studies. [Hong Kong J Nephrol 2004;6(1):2–13]
Key words: sickle cell, tubular, glomerular disease, papillary necrosis,
renal failure, ESRD
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INTRODUCTION
Sickle cell disease is a major public health problem in
the Eastern Province of Saudi Arabia. It is said to be
present in individuals heterozygous (Hb-S) or
homozygous (Hb-SS) for the hemoglobin S (HbS) gene.
The term sickle cell disease applies to homozygous
patients; heterozygotes are said to have sickle cell trait.
Sickle cell nephropathy is indicated by sickled
erythrocytes and is characterized by decreased
medullary blood flow, ischemia, microinfarcts, and
papillary necrosis. Tubular function, glomerular
filtration, blood pressure regulation, and water and
electrolyte metabolism are all disturbed (Table 1).
Although there are many studies showing that
proteinuria, nephritic syndrome, chronic progressive
renal failure, and acute renal failure syndromes are the
outcome of sickle cell nephropathy, the pathogenic
mechanisms and potential therapies remain to be
elucidated. Platt et al provide the most comprehensive
analysis of life expectancy and risk factors for early
death in sickle cell disease; 18% of deaths are ascribed
to chronic end-organ involvement, predominantly renal
[1]. Patients with sickle cell nephropathy who progress
to end-stage renal disease (ESRD) have similar survival
to those with non-diabetic ESRD [2]. This article pre-
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sents a review of the glomerular and tubular disorders
associated with sickle cell disease and points to relevant
pathophysiologic and clinical implications.
RENAL TUBULAR ABNORMALITIES
An inability to achieve maximally concentrated urine
is the most consistent feature of sickle cell nephropathy.
This inability has now been documented in both
homozygotes and heterozygotes [3–9]. It seems that
there is a relationship between concentrating capacity
and age. In Hb-SS patients more than 10 years old, the
maximal urinary concentration is reduced to about
400 mOsm/kg H2O and does not decrease further with
advancing age. In very young children with sickle cell
disease, a concentrating defect is present, but normal
concentrating ability can be restored by multiple
transfusions of Hb-A erythrocytes [4,7]. This capacity
for improvement is progressively lost with age, and in
patients older than 15 years, impaired concentrating
capacity is irreversible [7]. This is due to repeated
sludging that causes thrombosis, progressive infarction
of the inner medulla, and papillary necrosis [10,11]. In
heterozygotes, more gradual and smaller degrees of
impairment are seen [10,11].
The hypoxic, acidotic, and hyperosmolar envi-
ronment of the inner medulla is known to promote
sickling of erythrocytes with resultant impairment of
tubular function (Figure 1). Patients with sickle cell
disease have a significantly reduced number of vasa
recta and obliteration of the remaining medullary
capillaries with consequent disturbance in the
countercurrent multiplication and exchange system of
the inner medulla [10,12]. Defects in urinary diluting
capacity also occur. Patients with sickle cell disease
are capable of normal urine dilution [6,7,9]. Under
conditions of water diuresis, the fall in urinary
osmolality is the same in control subjects and Hb-SS
patients; this combination of a defect in renal
concentrating capacity and normal diluting capacity is
characteristic of sickle cell disease [5,12].
Renal acidification and potassium excretion are also
impaired in patients with sickle cell disease, and many
Table 1. Renal complications of sickle cell disease.
Complication Causes Comments
Urinary concentration defect Progressive infarction and Progresses with age
necrosis of papillae and inner medulla
Acidification defect Defect in [H+] ion excretion Inability to lower urine pH to < 5.3 following NH4Cl
Impaired potassium excretion Ischemic injury of the collecting ducts Not associated with hyperkalemia
Impaired urate clearance Ischemic injury of the distal tubules Progresses with age
Hyperphosphatemia Increased maximal tubular reabsorption Increased sodium reabsorption parallels
of phosphate phosphate reabsorption
Increased GFR () 50%) Compensatory hypersecretion of Both GFR and RBF are normal during adolescence
vasodilators
Decreased RBF Congestion of capillary loops with sickled Decreased ultrafiltration co-efficient with age
cells and hemosiderin; inflammatory
vasoactive substances
Papillary necrosis Occlusion of vasa recta and Incidence 15–36%; lower risk with higher levels of
medullary vessels fetal Hb or of Hb A2
Hematuria Medullary vascular occlusion by sickled Usually painless and self-limited;
RBCs; rarely renal medullary cancer 80–90% unilateral
Glomerular abnormalities Glomerular hyperfiltration; autoantigens/ FSGS/MPGN; usually no immune deposits;
and proteinuria cytokines; iron overload suspect renal vein thrombosis if massive proteinuria
Acute renal failure Volume depletion; severe sepsis; Hemodynamic stress of pregnancy may
rhabdomyolysis precipitate it
Chronic renal failure Progressive parenchymal damage and Incidence of 4–18% in adults in the United States
chronic glomerular disease
NH4Cl = ammonium chloride; GFR = glomerular filtration rate; RBF = renal blood flow; Hb = hemoglobin; RBCs = red blood cells;
FSGS = focal segmental glomerulosclerosis; MPGN = membranoproliferative glomerulonephritis.
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individuals may show a form of incomplete distal renal
tubular acidosis. Sickle cell disease patients are unable
to lower their urine pH to less than 5.3 following
standard ammonium chloride loading [13,14], which
is not seen in patients with sickle cell trait [15]. Under
normal conditions, patients with sickle cell disease do
not manifest acidosis unless the glomerular filtration
rate (GFR) is reduced to less than one-half of normal
[16]. Other points that differentiate it from classic renal
tubular acidosis type I include the absence of hypo-
kalemia, hypercalciuria, nephrocalcinosis, and nephro-
lithiasis [16].
In addition to the defect in hydrogen ion excretion,
potassium excretion is also impaired in sickle cell
disease patients [13,16,17]. After administration of
potassium chloride, sodium sulfate, or furosemide,
potassium excretion is subnormal in patients with sickle
cell disease; however, hyperkalemia has not been
reported in sickle cell disease patients unless there is
impairment of renal function or conditions of stress [13,
16]. Plasma renin activity and plasma aldosterone
concentrations in these patients are normal, both with
normovolemia and after volume contraction, so the
defect cannot be explained by hypoaldosteronism [16,
18]. DeFronzo et al suggest the presence of a primary
defect in the renal tubular secretion of potassium, which
is probably caused by ischemic injuries in the collecting
ducts [13]. Despite impaired potassium excretion, the
serum potassium concentration does not increase during
potassium loading, which suggests an increased intra-
cellular shift of potassium, probably caused by ß2
adrenergic stimulation [19]. Potassium excretion in
sickle cell trait is normal [20]. Few reports have des-
cribed hyporeninemic hypoaldosteronism in patients
with sickle cell disease [17,18]. In these cases, an
impaired renin-secreting apparatus may result in
impaired function of the adrenal glomerulosa cells,
diminished aldosterone secretion, and an impaired
ability to excrete potassium loads. In such cases, the
hyperkalemia responds favorably to treatment with
mineralocorticosteroids.
In spite of the severe disturbances in medullary
transport in patients with sickle cell disease, proximal
tubular activity, both secretory and reabsorptive,
appears to be supernormal. With increased red blood
cell (RBC) turnover and consequent uric acid over-
production, most patients with sickle cell disease are
normouricemic. Uric acid clearance is greater in these
patients [21,22]. Urate clearance, however, decreases
with age and the incidence of hyperuricemia increases
as renal function deteriorates [23]. In addition, the
tubular secretion of creatinine is increased in Hb-SS
patients compared to control subjects [24,25]. One
should realize, therefore, that creatinine clearance in
sickle cell disease overestimates GFR considerably.
Maximum tubular reabsorption of phosphate is also
increased in patients with sickle cell disease, so serum
phosphate is elevated in these patients [26,27]. It has
been postulated that the high phosphate reabsorption
reflects an increased reabsorptive activity in the
proximal tubules [26]. There is also increased sodium
reabsorption, which parallels phosphate reabsorption.
Some studies report an increased plasma volume in the
non-crisis steady state in sickle cell disease [28–30].
Increased reabsorption of ß-microglobulins has also
been described [31].
GLOMERULAR FILTRATION AND RENAL BLOOD
FLOW
GFR and renal blood flow (RBF) are increased by as
much as 50% in patients with sickle cell disease [24,
32]. This is probably related to compensatory hyper-
secretion of vasodilator prostaglandins during the
process of sickling. The filtration fraction is usually
decreased, indicating that increases in GFR are not
proportional to increases in RBF. Anemia per se
probably has some influence on these abnormalities
since similar changes have been observed in children
with ß-thalassemia [4]. However, other factors must
be involved since transfusion-associated increases in
hematocrit do not cause the renal hemodynamic para-
meters to revert to normal [4].
Bank et al recently studied the mechanism of
hyperfiltration in a transgenic sickle cell mouse model
Figure 1. Renal medullary changes that lead to hyposthenuria,
papillary necrosis, and hematuria. RBCs = red blood cells.
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and concluded that renal synthesis of nitric oxide by
the L-arginine pathway was increased in the transgenic
mice and that this increase correlated positively with
the GFR [33]. In a more recent study, the exposure of
transgenic sickle cell mice to chronic hypoxia resulted
in activation of inducible nitric oxide synthase and
superoxide radical and peroxynitrite formation; the
consequences of these reactions enhanced apoptosis,
ultimately leading to structural damage [34]. Whether
these mechanisms are operative in humans remains to
be proved.
Both GFR and RBF are normal during adolescence
but are frequently subnormal after the age of 40 [35,
36]. On the other hand, some patients with Hb-SS in
their 40s or even older may have completely normal or
even supernormal GFR and RBF [12]. Renal pathologic
findings in young patients with sickle cell disease
include glomerular enlargement as well as increased
numbers of capillary lumens and epithelial, endothelial,
and mesangial cells [37]. Other findings may include
congestion of capillary loops with sickled erythrocytes
and hemosiderin (Figures 2 and 3). Fractional creatinine
excretion is increased [24]. It is therefore advisable to
employ inulin clearance when investigating GFR. In
sickle cell trait, sickle cell-hemoglobin C disease,
homozygote-hemoglobin C disease, hemoglobin C trait,
and sickle cell ß-thalassemia, GFR and RBF are within
the normal range [3].
There is speculation on the possible mechanisms
responsible for the decline in renal hemodynamics with
age, sometimes ending in renal failure with shrunken
end-stage kidneys. Progressive renal insufficiency in
these patients has been ascribed to hyperfiltration-
mediated sclerosis of the glomerular capillaries [38,39].
In a recent study to determine the cause of progressive
renal insufficiency in patients with sickle cell disease,
Guasch et al found an association between renal insuf-
ficiency and a decrease in the ultrafiltration coefficient
[40]. The ultrafiltration coefficient was also reduced in
albuminuric patients with normal GFR [40]. This latter
finding supports the observation of Powars et al that
proteinuria and nephrotic syndrome are significant
preazotemic predictors of chronic renal failure [41]. The
results of another recent study by Schmitt et al seem to
contradict those of Guasch et al [42]. However, we can
speculate that proteinuria with an increase in the
ultrafiltration coefficient may represent very early
changes that act significantly to trigger the development
of glomerulosclerosis; these early changes may no
longer be detected at later stages, and a decrease in the
ultrafiltration coefficient may contribute to the decrease
in GFR. Remuzzi and Bertani suggest that filtered
plasma proteins taken up by tubular epithelium
stimulate inflammatory genes and release inflammatory
and vasoactive substances into the renal interstitium
that induce scarring and sclerosis [43].
PAPILLARY NECROSIS
Renal papillary necrosis is a frequent occurrence in both
sickle cell disease and sickle cell trait. As a complication
of sickle cell nephropathy, papillary necrosis has an
incidence of 15% to 36% [44]. Papillary necrosis in
sickle cell disease is mediated by blood vessel occlu-
sion, specifically of the vasa recta and medullary
vessels, that causes infarction and necrosis of papillary
tissue [45] (Figure 1). In most patients with sickle cell
disease, the infarcted areas are small, and renal function,
as measured clinically, is not usually immediately af-
fected [44]. Less commonly, sickle cell disease patients
have more widespread necrosis of the papillae due to
more extensive infarction [2]. Given that these patients
all have the same SS genotype, these data suggest that
Figure 2. Sickle cell nephropathy. Sickled erythrocytes in capillary
loops. (Jones’ silver stain with hematoxylin and eosin counter stain.)
Figure 3. Electron microscopic features of a large, congested
glomerulus. The capillary lumina are distended by sickled
erythrocytes. (Uranyl acetate and lead citrate, = 6,380.)
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individual variability in non-sickle cell disease genes
helps to determine the degree of blood vessel occlusion
with infarction. Thus, while HbS is caused by a single
mutation, sickle cell disease could be a multigene
disease [46]. This concept helps to account for the
variable severity of disease, including the degree of
papillary necrosis, among sickle cell disease patients.
Vessel occlusion is also affected by local production
of cytokines that alter local factors in a way that
augments vascular occlusion [47]. Sickle cell disease
patients with higher levels of fetal hemoglobin (HbF)
or of hemoglobin A2 have a lower risk for SS hemo-
globin polymerization and, hence, a lower risk for
infarction of papillary tissue with subsequent papilla-
ry necrosis [48]. In addition to HbS polymerization,
the degree to which sickled RBCs adhere to vascular
endothelium is an important component of the cascade
leading to blood vessel occlusion in sickle cell disease
[47]. Furthermore, immature and larger RBCs are
more likely than mature ones to adhere to vascular
endothelium [47]. There is individual variability among
sickle cell disease patients in their marrow response to
the increased RBC destruction that characterizes sickle
cell disease [49]; thus, variability in the release of
immature RBCs might contribute to individual
variability in the degree of vaso-occlusive disease,
including papillary necrosis, among these patients.
Papillary necrosis is most frequently found
incidentally during renal imaging procedures, formerly
intravenous pyelography (Figures 4 and 5) but now
more commonly ultrasound, computerized axial tomo-
graphy scan, or magnetic resonance imaging. The most
detailed analysis of reported series found 131 cases of
papillary necrosis in 334 patients with sickle cell disease
(39%), with the incidence ranging from 23% to 67% in
the individual series [44]. The true incidence of this
complication is probably higher, since many cases will
be asymptomatic or have only microscopic hematuria
that is not evident using imaging procedures [50]. The
mean age at discovery was 21 ( 1 years (range, 4–68
years) [44]. Papillary necrosis in sickle cell disease may
have a protracted course of months to years, interrupted
by recurring episodes of gross hematuria and/or urinary
tract infection [45]. Less commonly, it may present
dramatically with renal colic, gross hematuria, and acute
renal failure with or without urinary tract obstruction
[44,45,51]. Patients with sickle cell disease who develop
symptomatic papillary necrosis sometimes have blood
clots and/or sloughed papillary tissue in their urine,
although this finding was infrequent in one large series,
and acute urinary tract obstruction was even less fre-
quent [44]. Papillary necrosis is categorized accord-
ing to severity. The less severe variety is referred to as
the medullary or partial papillary form and is usually
confined to the tip of the papilla. When more advanced,
the forniceal architecture is preserved but types of
involvement may include the ring sign, sinus tract
formation, and cavity formation involving loss of part
or all of the papilla. Further progression to the total
papillary stage includes sinus tract formation at the
fornices, larger ring shadows indicative of larger
sequestrated papillae, and amputated calyces (Figure
6). Totally sloughed papillae may be seen as filling
defects in the renal pelvis, ureters, or bladder [44].
Figure 4. Intravenous pyelography showing renal papillary necrosis
with blunting of the calyces that is more marked in the left kidney.
Figure 5. Intravenous pyelography, demonstrating total papillary
necrosis with cavity formation (arrow) and a filling defect in the
renal pelvis due to sloughed papillae.
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HEMATURIA
In 1984, Abel and Brown discovered a relationship
between sickle cell disease and hematuria [52]. Hema-
turia is a major alteration detected in individuals with
sickle cell disease and sickle cell trait. It is usually
described as painless, symptomless, benign, and self-
limited, but it may also be hemorrhagic and difficult to
control. The pathogenesis of hematuria seems to be
explained by vascular obstruction in the renal medulla
by sickled RBCs, with consequent extravasation of
blood cells [53,54] (Figure 1). In 80% to 90% of cases,
the bleeding is unilateral and originates from the left
kidney, probably because of anatomic differences in
kidney venous drainage [55].
Mostofi and associates studied 21 kidneys from
patients with sickle cell disease that were removed
because of massive blood loss and the possibility of
renal neoplasm [56]. The absence of gross alterations
in most of these kidneys emphasizes the fact that the
lesions are inconspicuous and may be easily missed.
The most striking change was severe stasis in the
peritubular capillaries of both the cortex and the
medulla. Changes were most marked in the medulla.
Extravasation of blood was observed, mainly into the
collecting tubules. In 1990, Osegbe described 12
individuals (six with sickle cell disease) aged between
12 and 32 years with renal papillary necrosis diagnosed
by suggestive findings on excretory urography and mani-
fested by hematuria of 3 days’ to 5 months’ duration [57].
Bleeding was intense in four patients and moderate in
eight. Mild lumbar pain and fever occurred at low
frequency. Hematuria originated exclusively from the
left side in 10 of these patients.
Renal medullary carcinoma, of which the most
frequent symptom is massive hematuria, is a rare and
extremely aggressive tumor detected in association with
sickle cell trait, and more rarely with sickle cell hemo-
globinopathy. This tumor has not been reported
in homozygotes, a fact that remains unexplained. Cu-
riously, most of the bleeding occurring in this tumor
comes from the right kidney [58]. Renal medullary
carcinoma, although rare, should always be kept in mind
in the differential diagnosis of benign hematuria,
especially when the patient is a child or young adult
with sickle cell trait; renal imaging and urine cytology
should be performed in these patients [58,59].
More commonly, gross hematuria occurs in patients
who have heterozygous sickle hemoglobin (Hb-AS, Hb-
SC), as well as in those who have homozygous disease
[60–65]. The relative rarity of hematuria in patients with
Hb-SS is more apparent than real, as sickle cell trait is
approximately 40 times more common than the homo-
zygous state. Gross hematuria in affected patients may oc-
cur at any age, including young children, and appears
to be more common in males than in females [65,66].
GLOMERULAR ABNORMALITIES AND PROTEINURIA
The major pathologies in sickle cell disease-associated
renal failure are papillary necrosis, focal segmental
glomerulosclerosis (FSGS), and type 1 membrano-
proliferative glomerulonephritis (MPGN) [52]. Renal
biopsies in patients [37,38,45,67], as well as autopsy
studies, show that FSGS is the most common cause of
renal failure in sickle cell disease. Moreover, clinico-
pathologic studies show that the early lesion of most
forms of sickle cell nephropathy is glomerular en-
largement with progressive development of perihilar
FSGS [38,45]. These data support the hypothesis that
FSGS is the major cause of sickle cell nephropathy
(Figure 7).
Recent data suggest that sickle cell disease is a state
of oxidative stress [68]. It seems that initiation, progres-
sion, and resolution of the vaso-occlusive episodes
comprise features of ischemia-perfusion injury with the
associated chronic inflammatory response that includes
activation of white blood cells and a local increase
in the oxidative state [69]. Activated monocytes/
macrophages of bone marrow origin play an impor-
tant role in the pathogenesis of glomerulosclerosis in
humans [70]. In addition, oxidized plasma lipoproteins
are implicated in the pathogenesis of glomerulosclerosis
in experimental animals and in humans [69,71]. Factors
that probably cause FSGS in sickle cell disease are
summarized in Table 2.
Figure 6. Schematic diagram of the radiographic patterns of re-
nal papillary necrosis in patients with sickle cell disease: (A) nor-
mal calyx; (B) clubbed calyx; (C) filling defect; (D) ring shadow;
(E) amputated calyx.
A
B
C
D
E
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Although MPGN in sickle cell  disease is
morphologically similar to the classic variety of this
disease, few cases have the characteristic immune
deposits, particularly in the early stages [38,45]. Type
1 MPGN with immune complex deposits has been
documented in a small number of patients [2]. The
etiology of MPGN in sickle cell disease is poorly
understood, but it is not the major cause of renal failure
in sickle cell disease [45].
In sickle cell disease, glomerular size tends to
increase with age. Glomerular enlargement and
congestion are present in children more than 2 years
old [2,67]. Proteinuria has been detected by the dipstick
method in 17% to 33% of patients with sickle cell
disease, and seems to be associated with reduced
creatinine clearance in patients older than 40 years [67,
72]. Wigfall et al followed 442 patients with sickle cell
disease for 10 years; proteinuria lasting at least 6 months
was detected in 6% of children and 12% of adolescents
[73]. Proteinuria was associated with disease severity.
The mechanisms whereby nephrotic syndrome,
renal insufficiency, and glomerular lesions interrelate
in patients with sickle cell nephropathy remain unclear
[74]. Possible mechanisms include fortuitous
occurrence, iron overload and subsequent deposition
in the kidneys, mesangial phagocytosis of sickled cells,
immune complex glomerulonephritis due to auto-
antigens released from ischemic tubules, FSGS asso-
ciated with glomerular hyperfiltration, glomerular
hypertrophy, and endothelial damage [74,75]. Some
authors suggest that there must be a specific mecha-
nism associated with hemodynamic alteration in the patho-
genesis of sickle cell nephropathy, probably a change
in the glomerular capillary wall that leads to an altered
pore size [2,76]. It is also possible that the glomeruli
are sensitive to a common stimulus provoked by growth
hormone or cytokines [77–79].
Falk and colleagues found proteinuria of at least +1
in 101 of 381 (26.5%) patients with sickle cell disease
[67]. Among the 44 patients for whom there was
complete 24-hour urine collection, protein excretion
ranged from 0.028 to 10.8 g/24 hours (mean, 1.7 g/24
hours; standard deviation, SD, 2.4 g/24 hours). Twelve
patients excreted more than 2.5 g/24 hours, associated
with other features of the nephrotic syndrome. Sklar
and coworkers reviewed the records of 368 patients with
sickle cell disease [80]. Seventy-eight patients (20.6%)
had proteinuria and 17 patients (4.6%) had renal in-
sufficiency. Both renal insufficiency and proteinuria
increased with age. Renal vein thrombosis has been
diagnosed in some patients with sickle cell disease and,
because Hb-SS predisposes to venous thrombosis, this
complication should be considered in all patients with
Hb-SS in whom massive proteinuria develops.
Figure 7. Sickle cell nephropathy, focal segmental glomerulo-
sclerosis (FSGS). The segmental sclerotic lesion on the right with
FSGS is composed of obliteration of capillary lumens and increased
mesangial matrix. (Jones’ silver stain, = 400.)
Table 2. Factors that may induce focal segmental glomerulosclerosis in sickle cell disease.
Hyperfiltration of cortical nephrons due to:
  - Hypersecretion of vasodilator prostaglandins
  - Increased renal synthesis of nitric oxide
  - Cytokines from damaged vascular endothelium
Increased production of reactive oxygen species due to:
  - Hypoxia/reoxygenation
  - Recruitment of activated leukocytes
  - Auto-oxidation of sickle hemoglobin
Chronic exposure of tubular epithelium to high levels of filtered plasma proteins due to:
  - Cortical nephron hyperfiltration
  - Podocyte damage
  - Glomerular tuft adhesions
Autologous immune-complex nephritis due to:
  - Renal tubular epithelial antigens
  - Cryoprecipitable renal tubular antigen-antibody complexes
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ACUTE RENAL FAILURE
Acute renal failure has rarely been described in
association with sickle cell disease. Some reports
describe a reversible acute oliguric renal failure in the
setting of sickle cell crisis [81–83]. In these studies,
rhabdomyolysis was suggested as the cause of this acute
renal failure. In a study by Sklar et al, volume depletion
in the setting of sickle cell crisis was the most common
cause [84]. In more recent studies, episodes of acute
renal failure were most commonly noted in cases of
overwhelming sepsis with high fever [81–83], probably
due to diffuse microvascular occlusion and organ
ischemia or to non-traumatic rhabdomyolysis [82,83,
85]. Hassell and coworkers described a syndrome of
acute multi-organ failure involving the lung, liver, and
kidney in 14 sickle cell patients; this occurred during
an unusually severe painful crisis [83]. Pham and col-
leagues described a case of postpartum exacerbation
of sickle cell nephropathy manifested by nephrotic
syndrome and declining renal function [86], probably
due to the hemodynamic stress of pregnancy super-
imposed on a background of substantial chronic
nephron loss.
CHRONIC RENAL FAILURE
Renal function may deteriorate with age in sickle cell
disease patients, either as a result of the parenchymal
damage due to sickling or because of glomerular
disease. The incidence of renal failure in patients with
sickle cell disease is 4% to 18% in US adults [41,76].
Data from the US Renal Data System obtained for 1993
to 1997 showed that 0.1% of patients with ESRD had
sickle cell disease as a primary cause [87].
Both maintenance hemodialysis and renal
transplantation are viable options for patients with
sickle cell nephropathy who progress to ESRD. Survival
of patients on hemodialysis has been shown to be
equivalent to that of other non-diabetic ESRD patients
[88]. Although both graft and patient survival after
transplantation for sickle cell nephropathy-related
ESRD are slightly lower on a long-term basis than in
patients undergoing transplant for other causes, there
is a tendency towards a better survival of these patients
compared with those treated by dialysis [89]. Ojo et al
published the results of patient and allograft outcomes
in renal transplant recipients with ESRD secondary to
sickle cell nephropathy [89]. The study consisted of
22,647 African-American end-stage sickle cell nephro-
pathy patients who received kidney transplants between
1984 and 1996, identified through the United Network
of Organ Sharing (UNOS). One-year graft survival in
recipients with end-stage sickle cell nephropathy was
found to be similar to that in recipients with other causes
of ESRD. However, the 3-year cadaveric graft survival
was diminished among patients with sickle cell nephro-
pathy (48% vs 60%). Abbott et al analyzed 375,152
patients in the US Renal Data System who were
initiated on ESRD therapy between January 1992 and
June 1997 in a historical cohort study of sickle cell
nephropathy [90]. They found that sickle cell nephro-
pathy patients had an independently increased risk of
mortality. However, when renal transplantation was also
included in the model, sickle cell nephropathy was no
longer significant. Nevertheless, further analysis by
Scheinman revealed a trend toward better patient sur-
vival with renal transplantation compared with sickle
cell nephropathy patients on maintenance hemodialysis
[91]. Despite these encouraging results, renal transplan-
tation in sickle cell disease is not without morbidity.
An increase in the frequency of crisis has been demon-
strated in patients who undergo successful kidney trans-
plantation, which appears to be due to increased
endogenous hematopoiesis with a consequent increase
in blood viscosity and vaso-occlusive crisis [92–95].
Patients with sickle cell disease have a relative
erythropoietin deficiency. Steinberg described good
results when patients with sickle cell disease and
chronic renal failure used higher doses of epoetin-_
than are needed in patients with other forms of ESRD
[96]. However, the results obtained by Roger et al with
this drug in similar situations were disappointing [97].
Bone marrow transplantation has recently emerged
as a novel treatment for sickle cell disease. As this
procedure is associated with high morbidity and mor-
tality, it has been indicated in a relatively small number
of patients [98]. Whether bone marrow transplantat-
ion can stop the progression of sickle cell nephropathy
is unknown [2].
THERAPEUTIC ASPECTS
Treatment of hematuria
Efforts are needed to prevent or reverse sickling, to
prevent clot retention in the urinary tract, to increase
tissue oxygenation, and to reduce acidosis and hyper-
tonicity in the medulla. In this regard, the maintenance
of a high urinary flow is useful both for elimination of
blood clots and for reduction of renal medullary
osmolality, which in turn reduce RBC sickling in the
vasa recta. The fluid for infusion should be hypotonic;
up to 4 L/1.73 m2/day may be used. Urinary alkaliniza-
tion and blood transfusion when necessary may reduce
medullary sickling [99]. Drugs such as hydroxy-
carbamide (hydroxyurea) and recombinant human
erythropoietin increase the percentage of HbF in
patients with sickle cell disease, and may reduce
sickling. Some studies report an increase of about 15%
in HbF with the use of hydroxyurea [100]. Conflicting
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results, however, have been reported about its effect on
the number of sickling crises [101,102].
Nonsteroidal anti-inflammatory drugs
Nonsteroidal anti-inflammatory drugs (NSAIDs) are
often considered to be benign and preferable to opioids
for the treatment of pain in sickle cell disease. However,
particular risks of NSAID use do exist in these patients.
Blood loss from occult gastritis, although often un-
noticed in other patients, may destabilize precarious
hemodynamic compensation in chronic anemia. Since
NSAIDs and acetaminophen are used throughout life,
the risk of analgesic nephropathy must be considered,
especially in patients who are already at risk of renal
failure from sickle cell disease [103,104]. On the other
hand, isolated reports show no consistent benefits of
NSAIDs or immunosuppressive drugs such as steroids
and/or cyclophosphamide in the management of sickle
cell nephropathy [2,75].
Angiotensin-converting enzyme inhibitors
In the renal ablation animal model of FSGS, cha-
racterized by glomerular hyperfiltration and hyper-
tension, angiotensin-converting enzyme (ACE) inhi-
bitors decrease glomerular hyperfiltration and hyper-
tension and reduce the risk for subsequent development
of FSGS [105]. This observation encouraged inves-
tigators to test the efficacy of these drugs in reducing
both proteinuria and the likelihood of renal failure in
patients with sickle cell disease.
Foucan et al evaluated the effect of captopril on
microalbuminuria in sickle cell disease patients and
concluded that ACE inhibitors delay progression of
sickle cell nephropathy [106]. In their study of 381
patients with sickle cell disease, Falk et al found that
the mean 24-hour urinary protein excretion decreased
by about 57% below the baseline value (p < 0.001)
during the administration of enalapril in sickle cell
disease patients with nephropathy [67]. Longer-term
studies are needed, however, to determine whether this
ACE inhibitor-induced reduction in urinary albumin
excretion translates into a reduced risk of renal failure.
Interventions that reduce oxidant stress mediated
by reactive oxygen species might also reduce the risk
of nephropathy in sickle cell disease. Anti-oxidant
therapy, therefore, might retard FSGS progression in
such patients [69].
Management of tubular dysfunction
It is not usually necessary to treat tubular dysfunction.
Preventive measures, such as encouraging patients to
increase fluid ingestion in situations of greater water
loss, can be used to avoid complications. Diarrhea and
dehydration should be treated promptly, keeping in
mind that these patients have a lower ability to
concentrate urine and, hence, become dehydrated more
easily. Because tubular sodium reabsorption is in-
creased, possibly causing cardiac insufficiency, phy-
sicians must avoid prescribing large volumes with
standard sodium content for water repletion in these
patients [99]. Hyperuricemia can be aggravated by the
use of diuretics, particularly thiazides. During hemo-
lytic crises, the physician should be alert to the increase
in serum potassium. In these cases, the use of ß-blockers
or ACE inhibitors can aggravate hyperkalemia. A
ß-stimulant, on the other hand, may be important to
move this ion into cells [99]. Although indomethacin
reduces ammonia excretion [107], decreases sodium
tubular reabsorption, and improves the response to
diuretics [39], its use is not recommended because of
the significant fall in GFR and effective renal plasma
flow after indomethacin administration to Hb-SS
patients [24,25].
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